Astellas opens new Japanese research facilities
This article was originally published in Scrip
Astellashas inaugurated several new facilities at its existing research site in Tsukuba, Japan. The three laboratories, office and other facilities total 85,000m2, more than doubling the floor area at the campus, and cost ¥30 billion ($286.3 million) to build. All Japanese discovery functions, including in the pharmacology and chemistry areas, will be transferred to the site next spring. The move is part of a wider restructuring of domestic R&D facilities which will see the closure of a Tokyo research centre and the concentration of development research at the Kashima site near Osaka. Astellas has also dissolved its Fujisawa Ireland subsidiary in Killorglin, Ireland, following the transfer of all functions to Astellas Ireland, its main European production operation set up in 2005.
You may also be interested in...
Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.